Barinthus Biotherapeutics (BRNS) Treasury Shares (2021 - 2026)

Barinthus Biotherapeutics (BRNS) reported Treasury Shares of $792724.0 for Q1 2026, down 8.33% quarter-over-quarter from $864724.0 in Q4 2025.

Barinthus Biotherapeutics (BRNS) Treasury Shares (2021 - 2026) Analysis & Trends

Barinthus Biotherapeutics has reported Treasury Shares for 3 years, with the latest figure at $792724.0 in Q1 2026.

For the quarter ending Q1 2026, Treasury Shares changed N/A year-over-year to $792724.0; the trailing twelve-month figure through Mar 2026 stood at $792724.0 (changed N/A YoY), and the FY2025 full-year result was $864724.0, changed N/A from the prior year.
Treasury Shares for Q1 2026 stood at $792724.0, down from $864724.0 in the prior quarter.
The five-year high for Treasury Shares was $864724.0 in Q4 2025, with the low at $792724.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn	-
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-	1.48 Mn
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn	700,000.00
9	Abivax	94.37 Bn	94.37 Bn	-	-
10	Barinthus Biotherapeutics	27.08 Mn	-40.03 Mn	-	792,724.00

Download Data